Open Label Phase 4, 48 Week Pilot Study of the Antiviral Efficacy and Tolerability of the Combination of Isentress and Reyataz When Substituted for Current Antiviral Regimen in Patients With Viral Suppression But Who Are Experiencing Adverse Events Related to Their Current Antiviral Regimen.
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Atazanavir; Raltegravir
- Indications HIV infections
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 27 Sep 2008 New trial record.